Salcaprozate Sodium (SNAC) as an Oral Absorption Enhancer: Mechanism, Clinical Validation, and Implications for Peptide Drug Delivery

1. Background: The Challenge of Oral Delivery of Peptides

Peptide therapeutics represent one of the fastest-growing segments of modern pharmacology, yet their clinical utility has been constrained by the requirement for parenteral administration. The gastrointestinal tract presents a formidable series of barriers to oral peptide absorption: acidic gastric pH (1.0–3.0) drives conformational denaturation, luminal proteases including pepsin, trypsin, and chymotrypsin rapidly degrade unprotected peptide bonds, the mucus layer impedes diffusion, and the epithelial monolayer restricts paracellular and transcellular transit of hydrophilic macromolecules [Drucker, Nat Rev Drug Discov, 2020]. These barriers collectively limit oral bioavailability of most therapeutic peptides to well below 1%, rendering conventional oral formulation strategies ineffective.

The successful development of oral semaglutide co-formulated with SNAC represents a paradigm shift in this landscape. Approved by the FDA on September 20, 2019 (NDA 213051), Rybelsus® became the first oral GLP-1 receptor agonist and the first systemically acting oral peptide biologic incorporating a permeation enhancer [Buckley et al., Sci Transl Med, 2018]. The approach exploits a counterintuitive principle: rather than engineering the peptide itself for oral stability, the formulation creates transient, localized conditions in the stomach that enable sufficient absorption of the native molecule to achieve therapeutic plasma concentrations.

2. SNAC: Chemical and Physicochemical Profile

SNAC (IUPAC: sodium 8-[(2-hydroxybenzoyl)amino]octanoate; CAS 203787-91-1; molecular formula C₁₅H₂₀NNaO₄; molecular weight 301.32 Da) is structurally an N-acylated amino acid derivative consisting of a 2-hydroxybenzoyl (salicylamide) head group linked via an amide bond to an eight-carbon (caprylic) fatty acid chain terminated by a sodium carboxylate [Twarog et al., Pharmaceutics, 2019]. This architecture confers amphiphilicity: the aromatic salicylamide moiety provides hydrogen-bonding capacity and hydrophilic character, while the C8 alkyl chain imparts lipophilicity.

SNAC exhibits aqueous solubility of approximately 33 mg/mL and a critical micelle concentration (CMC) of approximately 56 mM in phosphate-buffered saline—substantially higher than conventional surfactants, reflecting the hydrophilic contributions of the salicylamide group [Twarog et al., Pharmaceutics, 2019]. This relatively high CMC is pharmacologically significant: at the concentrations achieved near the eroding tablet (~280 mM), SNAC operates well above its CMC, forming dynamic aggregates capable of interacting with both the peptide cargo and epithelial cell membranes.

SNAC was identified through systematic screening of a library of over 1,500 synthetic carrier compounds by Emisphere Technologies, Inc. (founded 1986; renamed 1991) as part of the proprietary Eligen® technology platform. The Eligen concept, developed under the scientific leadership of Sam Milstein, sought low-molecular-weight carriers capable of non-covalently chaperoning poorly permeable payloads across biological membranes without chemical modification of the drug or disruption of epithelial integrity [Aroda et al., Rev Endocr Metab Disord, 2022].

3. Mechanism of Action

The mechanism by which SNAC facilitates oral peptide absorption was elucidated primarily by Buckley et al. in a landmark 2018 study published in Science Translational Medicine, with subsequent refinements from solid-state NMR spectroscopy and molecular dynamics simulations. The process is transcellular, compound-specific, concentration-dependent, and fully reversible.

Step 1: Localized pH Buffering

Upon ingestion, the Rybelsus® tablet erodes in the stomach within approximately 60–90 minutes [Bækdal et al., Clin Pharmacol Drug Dev, 2021]. The 300 mg of SNAC creates a concentrated microenvironment (~280 mM) at the tablet–mucosa interface, raising local pH from the ambient gastric pH of 1–2 to approximately pH 5 or higher [Buckley et al., 2018; Colston et al., Nat Commun, 2025]. This pH shift substantially inactivates pepsin, whose proteolytic activity is negligible above pH 5, thereby protecting semaglutide from enzymatic degradation during the critical absorption window.

Step 2: Promotion of Semaglutide Monomerization

Semaglutide, like most GLP-1 analogs, self-associates into oligomeric complexes in solution through hydrophobic interactions. SNAC modifies the local polarity, weakening these intermolecular forces and shifting the equilibrium toward the monomeric form—the only species with sufficient diffusional mobility for transcellular passage [Buckley et al., 2018; Aroda et al., 2022].

Step 3: Membrane Fluidization and Transcellular Transport

SNAC embeds into the lipid bilayer of gastric epithelial cells, inducing a concentration-dependent increase in membrane fluidity. Quantitative solid-state NMR measurements demonstrated that SNAC enhances fluidity of the hydrophobic membrane core by 43% at 72 mM concentration, with lipid headgroup dynamics increasing by approximately 25% [solid-state NMR study, 2024]. This fluidization creates transient transcellular pathways—described by Colston et al. as “permeation-enhancer-filled membrane defects” operating through a dynamic, quicksand-like mechanism—through which monomeric semaglutide traverses the epithelium.

Critically, SNAC does not alter paracellular permeability. Head-to-head Caco-2 comparisons demonstrated that SNAC had no effect on transepithelial electrical resistance (TEER) or fluorescein dextran permeability—established markers of tight junction integrity—whereas sodium caprate (C10) reversibly opened tight junctions [Twarog et al., Eur J Pharm Biopharm, 2020]. Voltage clamp experiments confirmed a 7-fold increase in transcellular transport, five times greater than any paracellular contribution [Malkov et al., Pharm Res, 2002].

Step 4: Gastric-Specific Absorption

Unlike most oral drugs absorbed in the small intestine, SNAC–semaglutide absorption occurs predominantly in the stomach. Pyloric ligation studies in dogs demonstrated equivalent plasma semaglutide concentrations with and without intestinal access. Venous sampling revealed significantly higher semaglutide levels in the splenic vein (draining the gastric cavity) compared with the portal vein [Buckley et al., 2018]. Pharmacoscintigraphic imaging in humans confirmed that absorption is confined to the area proximal to the eroding tablet [Bækdal et al., 2021].

Step 5: Non-Covalent, Reversible Dissociation

The SNAC–semaglutide interaction is non-covalent, weak, and transient. Upon reaching the systemic circulation, the carrier and drug fully dissociate, with semaglutide entering the bloodstream in its pharmacologically active form—identical to the subcutaneously injected molecule [Twarog et al., Int J Pharm, 2022]. SNAC itself is rapidly eliminated (half-life ~2 hours) via β-oxidation and glucuronidation, with urinary excretion as the primary route.

4. Pharmacokinetics and Pharmacodynamics Impact

The oral bioavailability of semaglutide co-formulated with SNAC is approximately 0.4–1%, with population pharmacokinetic modeling estimating a mean of 0.8% under recommended dosing conditions [Overgaard et al., Clin Pharmacokinet, 2021]. This means that from a 14 mg oral dose, roughly 0.1 mg reaches systemic circulation. Despite this low fractional absorption, therapeutic efficacy is achievable because semaglutide possesses two compensating pharmacological properties: extraordinarily high receptor potency (picomolar binding affinity for the GLP-1 receptor) and a prolonged elimination half-life of approximately one week (152–160 hours), identical regardless of administration route [systematic PK review, 2024].

Within-subject variability in single-dose bioavailability is substantial at approximately 137% coefficient of variation, reflecting stochastic variations in gastric conditions at the time of absorption. However, the accumulation effect of once-daily dosing combined with the week-long half-life attenuates this variability to approximately 33% at steady state—a clinically manageable range [Overgaard et al., 2021]. Steady-state plasma concentrations are achieved after 4–5 weeks of daily administration, with the 14 mg oral dose producing exposure levels overlapping those of subcutaneous semaglutide 1.0 mg.

The stringent dosing requirements reflect the fragility of the absorption process. Each tablet must be taken in the fasting state with no more than 120 mL of plain water, followed by at least 30 minutes before food, beverages, or other oral medications. The rationale is physicochemical: food and excess fluid dilute the SNAC concentration below the threshold required for effective membrane interaction, physically displace the tablet from the gastric wall, and may accelerate transit beyond the gastric absorption window. In fed-state studies, 14 of 26 subjects had no quantifiable semaglutide absorption [FDA Clinical Pharmacology Review, NDA 213051]. Lower water volumes (50 mL vs. 240 mL) increased AUC and Cmax by approximately 70%, supporting the concentration-dependent nature of SNAC’s action [Bækdal et al., 2021].

5. Regulatory and Clinical Validation: The PIONEER Program

The Peptide InnOvatioN for Early diabEtes tReatment (PIONEER) program comprised 10 phase 3a randomized controlled trials enrolling 9,543 adults with type 2 diabetes across the full spectrum of disease severity and treatment backgrounds.

PIONEER 1 (monotherapy; n=703) demonstrated placebo-adjusted HbA1c reductions of −0.6%, −0.9%, and −1.1% for oral semaglutide 3, 7, and 14 mg, respectively (all p<0.001), with corresponding weight reductions of up to 2.3 kg [Aroda et al., Diabetes Care, 2019]. Active-comparator trials established that oral semaglutide 14 mg was superior to empagliflozin 25 mg for HbA1c reduction (PIONEER 2; estimated treatment difference −0.4%; p<0.0001) [Rodbard et al., Diabetes Care, 2019], superior to sitagliptin 100 mg (PIONEER 3; ETD −0.5%; p<0.001) [Rosenstock et al., JAMA, 2019], and noninferior to subcutaneous liraglutide 1.8 mg for glycemic control while achieving superior weight loss (−4.4 vs. −3.1 kg; p=0.0003) in PIONEER 4 [Pratley et al., Lancet, 2019]. PIONEER 5 confirmed efficacy and safety in moderate renal impairment without dose adjustment [Mosenzon et al., Lancet Diabetes Endocrinol, 2019], while PIONEER 8 demonstrated efficacy as add-on to insulin therapy [Zinman et al., Diabetes Care, 2019].

The cardiovascular evidence has matured substantially. The preapproval PIONEER 6 trial (n=3,183; median 15.9 months) confirmed noninferiority for major adverse cardiovascular events (MACE; HR 0.79; 95% CI 0.57–1.11; p<0.001 for noninferiority), with notable numerical reductions in cardiovascular death (HR 0.49) and all-cause mortality (HR 0.51) [Husain et al., N Engl J Med, 2019]. The definitive SOUL cardiovascular outcomes trial (n=9,650; mean follow-up 47.5 months) subsequently demonstrated a statistically significant 14% relative risk reduction in three-point MACE (HR 0.86; 95% CI 0.77–0.96; p=0.006), leading to FDA approval of a cardiovascular risk reduction indication in October 2025 [McGuire et al., N Engl J Med, 2025].

6. The Eligen® Technology Platform

SNAC’s development trajectory spans three decades. Emisphere Technologies screened its carrier library across multiple therapeutic payloads prior to the semaglutide partnership. Oral heparin co-formulated with SNAC reached phase II trials for deep vein thrombosis prophylaxis, demonstrating anticoagulant absorption comparable to subcutaneous dosing [Berkowitz et al., Circulation, 1998]. A related Eligen carrier, 5-CNAC (disodium N-(5-chlorosalicyloyl)-8-aminocaprylic acid), advanced to phase III for oral salmon calcitonin in osteoporosis and osteoarthritis in collaboration with Novartis, though trials ultimately did not meet primary efficacy endpoints. SNAC with native GLP-1 demonstrated rapid oral absorption with physiologically relevant insulin release in a phase I investigator-sponsored study [Beglinger, Clin Pharmacol Ther, 2008].

The first commercial Eligen product, Eligen B12 (oral cyanocobalamin/SNAC), launched in 2015 as an FDA medical food, concurrent with SNAC achieving Generally Recognized as Safe (GRAS) status for use up to 250 mg/day in dietary supplements [Castelli et al., Clin Ther, 2011]. The exclusive partnership between Emisphere and Novo Nordisk, initiated in June 2008 for GLP-1 formulations, expanded in 2016 to encompass four classes of metabolic disorder molecules. In November 2020, Novo Nordisk acquired Emisphere Technologies outright for $1.8 billion ($1.35 billion for shares plus $450 million for royalty obligations), securing full ownership of the Eligen SNAC platform.

7. Safety Profile and Long-Term Considerations

SNAC’s toxicological profile is characterized by a wide safety margin. Subchronic oral toxicity studies in Wistar rats established a no-observed-adverse-effect level (NOAEL) of 1,000 mg/kg/day over 13 weeks—approximately 230-fold the human clinical dose of ~4.3 mg/kg [Riley et al., Int J Toxicol, 2009]. Developmental toxicity assessment at this same extreme dose showed no effects on offspring growth, development, sexual maturation, or fertility, though prolonged gestation and increased stillbirths occurred at this supra-therapeutic exposure [Riley and York, Int J Toxicol, 2009].

Gastrointestinal adverse events observed with Rybelsus (nausea, vomiting, diarrhea, decreased appetite)—reported in approximately 39% of patients versus 25% with comparators across PIONEER trials—are attributable to the pharmacological class effects of GLP-1 receptor agonism rather than SNAC, as subcutaneous semaglutide produces nearly identical GI adverse event rates (~42%) [Christensen et al., 2023]. The SOUL trial provides the longest controlled exposure dataset, with four years of daily 300 mg SNAC administration yielding no new safety signals and fewer serious adverse events with semaglutide (47.9%) than placebo (50.3%) [McGuire et al., 2025].

The Rybelsus prescribing information carries a boxed warning for thyroid C-cell tumors observed with semaglutide in rodents—a semaglutide-related finding of unknown human relevance, not attributable to SNAC. SNAC-specific labeling concerns are limited to lactation, where SNAC and/or metabolites were detected in rat milk at concentrations 2–12-fold higher than plasma.

8. Broader Implications for Drug Development

The commercial success of Rybelsus® has validated the feasibility of oral peptide delivery at scale. Beyond the direct therapeutic applications in diabetes and cardiovascular risk reduction, the SNAC platform has broader implications for patient adherence and market access. Injection reluctance remains a significant barrier to GLP-1 therapy initiation, with survey data suggesting that 20–30% of eligible patients decline injectable treatments. The availability of an oral alternative expands the addressable patient population and enables earlier intervention in the disease course [Indian J Endocrinol Metab review, 2022].

From a formulation science perspective, SNAC’s regulatory approval established the precedent that an absorption enhancer can be incorporated as a pharmaceutical excipient in an oral dosage form for systemic drug delivery. This regulatory pathway—documenting excipient safety, demonstrating consistent pharmacokinetic performance, and validating clinical outcomes—provides a template for future oral biologic programs regardless of the specific enhancer technology employed.

9. Limitations and Scientific Controversies

Several limitations define the current ceiling of SNAC-based oral peptide delivery. The approximately 1% bioavailability necessitates oral doses 14-fold higher than subcutaneous equivalents, with manufacturing and cost implications. The 137% dose-to-dose absorption variability exceeds that of virtually any other oral drug class, though steady-state averaging mitigates clinical impact. The strict fasting, water volume, and post-dose waiting requirements create adherence burdens that may reduce real-world effectiveness compared to trial settings.

The gastric-only absorption window presents a fundamental constraint. Once the dissolved drug transits the pylorus, the absorption opportunity is essentially lost, creating a narrow temporal and spatial window dependent on gastric motility, tablet positioning, and local fluid dynamics. The concentration-dependent mechanism requires co-formulation rather than co-administration, as the geometric proximity of SNAC and semaglutide at the tablet surface is essential for the localized microenvironment [Buckley et al., 2018].

Mechanistic debate persists. While transcellular transport is established, the relative contributions of pH buffering, membrane fluidization, and direct peptide–carrier complexation remain incompletely resolved. Twarog et al. (2019) noted that the lipophilic complex formation theory advanced in early Emisphere literature is “problematic in several respects,” favoring membrane perturbation as the primary driver. The 2025 CpHMD simulation study by Colston et al. introduced the concept of fluid, SNAC-filled membrane defects, suggesting a more nuanced mechanism than simple fluidization. Importantly, SNAC’s absorption-enhancing effect is compound-specific—liraglutide, which differs from semaglutide primarily in its fatty acid side chain and consequent stronger membrane binding and oligomerization tendency, showed significantly lower plasma exposure when co-formulated with SNAC under identical conditions [Buckley et al., 2018].

10. Future Research Directions

The landscape of oral peptide and biologic delivery is evolving rapidly across multiple technological paradigms.

Second-generation oral semaglutide. Novo Nordisk’s 2G oral semaglutide formulation achieves improved bioavailability, enabling equivalent therapeutic exposure at reduced API doses of 1.5, 4, and 9 mg (replacing the first-generation 3, 7, and 14 mg tablets), with confirmed bioequivalence across regulatory jurisdictions. A 25 mg oral semaglutide tablet was approved for chronic weight management in December 2025.

Small-molecule GLP-1 receptor agonists. These represent a fundamentally different approach that bypasses the peptide delivery problem entirely. Orforglipron (Eli Lilly), the most advanced non-peptide oral GLP-1RA, requires no food or water restrictions—a major practical advantage—and demonstrated HbA1c reductions of 1.3–1.6% in the phase III ACHIEVE-1 trial. However, Pfizer’s danuglipron was discontinued in 2025, highlighting development risks in this chemical class [MDPI oral GLP-1 review, 2025].

Device-based approaches. The self-orienting millimeter-scale applicator (SOMA), developed collaboratively by MIT, Brigham and Women’s Hospital, and Novo Nordisk, uses a leopard tortoise–inspired geometry for passive gastric self-orientation, delivering drug-loaded milliposts directly through the gastric mucosa to achieve insulin plasma levels comparable to subcutaneous injection in preclinical models [Abramson et al., Science, 2019]. Rani Therapeutics’ RaniPill, an enteric-coated microneedle capsule targeting the small intestine, has demonstrated subcutaneous-equivalent bioavailability for teriparatide in phase I.

Ionic liquid formulations. Choline-based ionic liquids, particularly choline and geranic acid (CAGE) and choline decanoate ionogels, have achieved oral insulin bioavailability of 2–6.5% in animal models—several-fold improvements over SNAC-class enhancers [Raptis et al., Adv Healthcare Mater, 2025]. Notably, a SNAC-based ionic liquid (choline salcaprozate, CHONAC) has been developed for oral GLP-1 delivery, demonstrating faster onset than tablet formulations.

11. Conclusion

SNAC represents both a proof of concept and a technological inflection point for oral peptide delivery. Its incorporation into Rybelsus® validated the commercial viability of permeation-enhanced oral peptide formulations despite sub-1% bioavailability, establishing regulatory precedent and clinical evidence across more than 19,000 patients in controlled trials. The mechanistic understanding has progressed from early lipophilic complexation models through the definitive transcellular absorption data of Buckley et al. (2018) to the dynamic membrane defect simulations of 2025—yet fundamental questions about the relative contributions of pH buffering, membrane fluidization, and peptide–carrier interaction remain. The strict dosing constraints and high absorption variability inherent to SNAC-mediated delivery create tangible limitations that next-generation platforms—small-molecule agonists, ingestible devices, ionic liquids, and improved formulations—are designed to address. SNAC’s legacy will likely be defined less by its continued clinical dominance than by the scientific and regulatory pathway it established, demonstrating that a well-chosen peptide, combined with an absorption enhancer operating at the margin of pharmacological feasibility, can achieve meaningful therapeutic outcomes through the oral route.

References

1. Buckley ST, Bækdal TA, Vegge A, et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Science Translational Medicine. 2018;10(467):eaar7047. DOI: 10.1126/scitranslmed.aar7047
2. Twarog C, Fattah S, Heade J, Maher S, Fattal E, Brayden DJ. Intestinal permeation enhancers for oral delivery of macromolecules: a comparison between salcaprozate sodium (SNAC) and sodium caprate (C10). Pharmaceutics. 2019;11(2):78. DOI: 10.3390/pharmaceutics11020078
3. Bækdal TA, Borregaard J, Hansen CW, Thomsen M, Anderson TW. Relationship between oral semaglutide tablet erosion and pharmacokinetics: a pharmacoscintigraphic study. Clinical Pharmacology in Drug Development. 2021;10(5):453–462. DOI: 10.1002/cpdd.938
4. Colston JN, et al. Permeation enhancer-induced membrane defects assist the oral absorption of peptide drugs. Nature Communications. 2025;16:5671. DOI: 10.1038/s41467-025-64891-0
5. Overgaard RV, Navarria A, Ingwersen SH, Bækdal TA, Kildemoes RJ. Clinical pharmacokinetics of oral semaglutide: analyses of data from clinical pharmacology trials. Clinical Pharmacokinetics. 2021;60:1335–1348. DOI: 10.1007/s40262-021-01025-x
6. Aroda VR, Saugstrup T, Buse JB, Donsmark M, Zacho J, Davies MJ. Incorporating and interpreting regulatory guidance on estimands in diabetes clinical trials: the PIONEER 1 randomized clinical trial as an example. Diabetes, Obesity and Metabolism. 2019;21(10):2203–2210. DOI: 10.2337/dc19-0133
7. Rodbard HW, Rosenstock J, Canani LH, et al. Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial. Diabetes Care. 2019;42(12):2272–2281. DOI: 10.2337/dc19-0883
8. Pratley R, Amod A, Hoff ST, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4). Lancet. 2019;394(10192):39–50. DOI: 10.1016/S0140-6736(19)31271-1
9. Mosenzon O, Blicher TM, Rosenlund S, et al. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5). Lancet Diabetes Endocrinol. 2019;7(7):515–527. DOI: 10.1016/S2213-8587(19)30192-5
10. Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine. 2019;381(9):841–851. DOI: 10.1056/NEJMoa1901118
11. McGuire DK, et al. Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes (SOUL). New England Journal of Medicine. 2025. DOI: 10.1056/NEJMoa2501006
12. Zinman B, Aroda VR, Buse JB, et al. Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: the PIONEER 8 trial. Diabetes Care. 2019;42(12):2262–2271. DOI: 10.2337/dc19-0898
13. Malkov D, Wang HZ, Bhatt S, et al. Oral delivery of low molecular weight heparin and unfractionated heparin in rabbits. Pharmaceutical Research. 2002;19(6):818–823.
14. Malkov D, Angelo R, Wang HZ, et al. Investigation of the enhancing mechanism of SNAC on intestinal permeability. European Journal of Pharmaceutical Sciences. 2005;26(3–4):286–293. DOI: 10.1016/j.ejps.2005.06.009
15. Riley MGI, Castelli MC, Paehler EA. Subchronic oral toxicity of salcaprozate sodium (SNAC) in Sprague-Dawley and Wistar rats. International Journal of Toxicology. 2009;28(4):278–293. DOI: 10.1177/1091581809337738
16. Riley MGI, York RG. Peri- and postnatal developmental toxicity of salcaprozate sodium (SNAC) in Sprague-Dawley rats. International Journal of Toxicology. 2009;28(4):266–277. DOI: 10.1177/1091581809337736
17. Berkowitz SD, Marder VJ, Kosutic G, Baughman RA. Oral heparin administration with a novel drug delivery agent (SNAC) in healthy volunteers and patients undergoing elective total hip arthroplasty. Circulation. 1998;98(16):1610–1615. DOI: 10.1161/01.CIR.98.16.1610
18. Aroda VR, Blonde L, Engmose JH. A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes. Reviews in Endocrine and Metabolic Disorders. 2022;23:979–994. DOI: 10.1007/s11154-022-09735-8
19. Christensen RM, et al. Current understanding of sodium N-(8-[2-hydroxylbenzoyl] amino) caprylate (SNAC) as an absorption enhancer: the oral semaglutide experience. Clinical Diabetes. 2024;42(1):74–82. DOI: 10.2337/cd23-0049
20. U.S. Food and Drug Administration. Clinical pharmacology review: NDA 213051 (Rybelsus). FDA Accessdata. 2019.
21. U.S. Food and Drug Administration. Rybelsus (semaglutide) prescribing information. FDA Label 2025.
22. Victor S, Anna M, Insung C. Eligen® technology for oral delivery of proteins and peptides. In: Oral Drug Delivery Technologies. 2014. Chapter 18.
23. Raptis V, et al. Salcaprozate-based ionic liquids for GLP-1 gastric delivery: a mechanistic understanding of in vivo performance. Journal of Controlled Release. 2024. DOI: 10.1016/j.jconrel.2024.11.013